Human Microbiome Market 2018 - 2025: Enterome, MicroBiome Therapeutics, LLC, Rebiotix Inc., Yakult Honsha Co., Ltd., Osel Inc., Vedanta Biosciences, Inc., Metabiomics Corporate, Synthetic Biologics, Inc., DuPont, and BiomX

The global human microbiome market accounted to US$ 257.30 Mn in 2017 and is expected to grow at a CAGR of 21.8% during the forecast period 2018 - 2025, to account to US$ 1,197.08 Mn by 2025.

The market for human microbiome is expected to grow as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in metagenomics and next-generation sequencing are expected to fuel the market growth during the forecast period. In addition, the human microbiome - a new frontier in drug discovery is likely to have a positive impact on the growth of the market in the coming years.

Get PDF sample copy: http://bit.ly/2VO9Tm2

Over the past few decades, human microbiome is related to lifestyle diseases like cancer, diabetes, obesity, depression and many others. Changes in lifestyles and societal norms influence the microbiome at each stage of life. Altering the human microbiome can help in eliminating such lifestyle diseases. As per World health organization in 2016, 13% of the world population (adults) were obese. According to the “The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation” published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), which involves the transfer of feces from a healthy donor to the patient, is a potential treatment for obesity

Probiotics Segment is expected to grow the Market for Human Microbiome over the Forecast Period for Product Segment.

The major players operating in the human microbiome market include Enterome, MicroBiome Therapeutics, LLC, Rebiotix Inc., Yakult Honsha Co., Ltd., Osel Inc., Vedanta Biosciences, Inc., Metabiomics Corporate, Synthetic Biologics, Inc., DuPont, and BiomX Ltd. For instance, in April 2018, MicroBiome Therapeutics, LLC (MBT), announced the launch of BiomeBliss, a patented, first-in-class prebiotic dietary supplement specifically developed to support a healthy gastrointestinal (GI) microbiome. Developed by pioneering researchers and entrepreneurs, BiomeBliss nourishes, shifts and protects the GI microbiome ? the trillions of gut bacteria that affect health. The developments performed by the companies are helping the market to grow in the coming years.

Buy the complete report @ http://bit.ly/2VOa294

Strategic Insights

Expansion and patent and license approvals were observed as the most adopted strategy in global human microbiome industry. Few of the recent expansions and license as well as patent approvals made by the players are listed below:

2018: In April, 2018, MicroBiome Therapeutics, LLC (MBT), announced the launch of BiomeBliss, a patented, first-in-class prebiotic dietary supplement specifically developed to support a healthy gastrointestinal (GI) microbiome.

2017: In June, 2017, Guangzhou Yakult Co., Ltd. in Guangdong Province, China, would start constructing the Foshan Plant in Foshan, Guangdong Province in July 2017 for production of the Yakult and Yakult Light.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Web: https://www.theinsightpartners.com/

This release was published on openPR.